Table 1. Prevalence of HBV and HCV infection in patients with different types of B-cell non-Hodgkin lymphoma.
| Category | Total (N) |
HBs-Ag infection rate |
Unadjusted odds ratio (95% CI) | P value |
HCV infection rate |
Unadjusted odds ratio (95% CI) | P value | ||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | ||||||
| General population | 81 775 | 5888 | 7.2 | Reference | |||||
| General population | 78 746 | 316 | 0.40 | Reference | |||||
| B-NHL patients | 881 | 79 | 9.0 | 1.270 (1.006-1.602) | 0.044 | 16 | 1.8 | 4.606 (2.775-7.645) | 0.000 |
| Indolent B-NHL | 733 | 58 | 7.9 | 1.107 (0.846-1.450) | 0.458 | 14 | 1.9 | 4.848 (2.824-8.322) | 0.000 |
| Aggressive B-NHL | 148 | 21 | 14.2 | 2.131 (1.342-3.384) | 0.001 | 2 | 1.35 | 3.411 (0.841-13.828) | 0.068 |
| According to indolent lymphoma subtype | |||||||||
| SMZL | 48 | 9 | 18.8 | 2.974 (1.440-6.143) | 0.002 | 2 | 4.2 | 10.826 (2.617-44.788) | 0.000 |
| CLL | 279 | 21 | 7.5 | 1.049 (0.672-1.638) | 0.833 | 6 | 2.2 | 5.472 (2.419-12.380) | 0.000 |
| LPL/WM | 119 | 6 | 5.1 | 0.684 (0.301-1.556) | 0.363 | 3 | 2.6 | 6.439 (2.036-20.366) | 0.000 |
| FL | 74 | 6 | 8.1 | 1.137 (0.493-2.621) | 0.763 | 0 | 0 | 0.586 | |
| B-LPDu | 132 | 10 | 7.5 | 1.056 (0.554-2.014) | 0.868 | 1 | 0.76 | 1.901 (0.265-13.636) | 0.516 |
| HCL | 33 | 4 | 12.5 | 1.778 (0.625-5.058) | 0.274 | 1 | 3.0 | 7.781 (1.060-57.116) | 0.017 |
| NMZL | 27 | 3 | 11.1 | 1.611 (0.485-5.352) | 0.432 | 1 | 3.7 | 9.576 (1.296-70.786) | 0.007 |
| MALT | 15 | 0 | 0 | 0.281 | 0 | 0 | 0.806 | ||
| B-PLL | 6 | 0 | 0 | 0.495 | 0 | 0 | 0.877 | ||
| According to aggressive lymphoma subtype | |||||||||
| DLBCL | 58 | 12 | 20.7 | 3.362 (1.780-6.350) | 0.000 | 0 | 0 | 0.629 | |
| MCL | 59 | 8 | 13.6 | 2.022 (0.959-4.262) | 0.059 | 2 | 3.5 | 9.054 (2.199-37.279) | 0.000 |
| Burkitt lymphoma | 2 | 0 | 0 | 0.694 | 0 | 0 | 0.929 | ||
| B-LBL | 14 | 0 | 0 | 0.297 | 0 | 0 | 0.813 | ||
| Aggressive B-NHL unclassified | 15 | 1 | 6.7 | 0.921 (0.121-7.002) | 0.936 | 0 | 0 | 0.806 | |
Abbreviations: B-LBL, B-cell lymphoblastic lymphoma; B-LPDu, unclassified B-cell chronic lymphoproliferative disorders; B-NHL, B-cell non-Hodgkin Lymphoma; B-PLL, B-cell prolymphocytic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; HBV, hepatitis B virus; HCL, hairy cell leukemia; HCV, hepatitis C virus; FL, follicular lymphoma; LPL/WM, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MALT, mucosa-associated lymphoma; MCL, mantle cell lymphoma; NMZL, nodal marginal zone lymphoma; SMZL, splenic marginal zone lymphoma. P value comes from comparison with general population; bold indicates significant difference (P<0.05).